# Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

> **NCT00839982** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Myelodysplastic Syndrome With Isolated Del(5q)
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT00839982
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839982, "Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00839982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*